Cyclacel Pharmaceuticals Inc. has always been a product play. Since its foundation in 1996 the Scottish biotech has focused on R&D of cell-cycle modulating compounds, building on the pioneering discoveries of CSO and founder David Lane, PhD. And in this single-mindedness is Cyclacel's staying power. "We weren't the most interesting game in town in 2000" when the genomics revolution attracted most VC funding to platforms, "but that's the way it works," says Cyclacel CEO Spiro Rombotis.
Indeed, even during the sobering genomic aftermath, when investor interest switched to late-stage products, Cyclacel didn't jump on that bandwagon...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?